# EDGAR Filing Document

**Accession Number:** 0001837821
**File Stem:** 0001213900-23-018100
**Filing Date:** 2023-3
**Character Count:** 17655
**Document Hash:** e4a1bb14cfc87f002a65225604aabd22
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-018100.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001213900-23-018100

**CONFORMED SUBMISSION TYPE**: F-1/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jin Medical International Ltd.
- **CENTRAL INDEX KEY:** 0001837821
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** F-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-259767
- **FILM NUMBER:** 23711913

**BUSINESS ADDRESS:**
- **STREET 1:** NO. 33 LINGXIANG ROAD, WUJIN DISTRICT
- **STREET 2:** CHANGZHOU CITY
- **CITY:** JIANGSU PROVINCE
- **STATE:** F4
- **ZIP:** 213149
- **BUSINESS PHONE:** (86)51989607972

**MAIL ADDRESS:**
- **STREET 1:** NO. 33 LINGXIANG ROAD, WUJIN DISTRICT
- **STREET 2:** CHANGZHOU CITY
- **CITY:** JIANGSU PROVINCE
- **STATE:** F4
- **ZIP:** 213149

**As filed with the U.S. Securities and Exchange Commission on March 7, 2023**

**Registration No. 333-259767**

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**AMENDMENT NO. 12**

**TO**

**FORM F-1<br> REGISTRATION STATEMENT<br> UNDER<br> THE SECURITIES ACT OF 1933**

**JIN MEDICAL INTERNATIONAL LTD.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **3790** | **Not Applicable** |
| (State or other jurisdiction of<br> incorporation or organization) | (Primary Standard Industrial<br> Classification Code Number) | (I.R.S. Employer<br> Identification Number) |

---

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People's Republic of China<br> +86-519 89607972

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Cogency Global Inc.

122 E. 42nd Street, 18th Floor

New York, NY 10168<br> (212) 947-7200

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***With a Copy to:***

---

| | |
|:---|:---|
| **Ying Li, Esq.**<br> **Lisa Forcht, Esq.<br> Hunter Taubman Fischer & Li LLC**<br> **48 Wall Street, Suite 1100**<br> **New York, NY 10005**<br> **Tel: 1-212-530-2206** | **Anthony W. Basch, Esq.** <br> **Chenxi Lu, Esq.**<br> **Kaufman & Canoles, P.C.**<br> **Two James Center, 14th Floor**<br> **1021 East Cary Street**<br> **Richmond, Virginia 23219**<br> **Tel: 1-804-771-5700** |

---

**Approximate date of commencement of proposed sale to the public:** Promptly after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933

Emerging growth company ☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.**

**EXPLANATORY NOTE**

JIN MEDICAL INTERNATIONAL LTD. is filing this Amendment No. 12 to its registration statement on Form F-1 (File No. 333-259767) (the "Registration Statement") as an exhibits-only filing. Accordingly, this amendment consists only of the facing page, this explanatory note, the Exhibit Index, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 1.1 | [Form of Underwriting Agreement\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022055638/ea165658ex1-1_jinmedical.htm) |
| 3.1 | [Memorandum and Articles of Association\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex3-1_jinmedical.htm) |
| 3.2 | [Form of Amended and Restated Memorandum and Articles of Association\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex3-2_jinmedical.htm) |
| 4.1 | [Registrant's Specimen Certificate for Ordinary Shares\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex4-1_jinmedical.htm) |
| 4.2 | [Form of Representative's Warrant\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022055638/ea165658ex4-2_jinmedical.htm) |
| 5.1 | [Opinion of Maples and Calder (Hong Kong) LLP regarding the validity of the Ordinary Shares being registered\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390023014263/ea173808ex5-1_jinmedical.htm) |
| 8.1 | [Opinion of Beijing Dacheng Law Office, LLP (Shanghai) regarding certain PRC tax matters (included in Exhibit 99.3)\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-3_jinmedical.htm) |
| 8.2 | [Opinion of Hunter Taubman Fisher & Li LLC regarding certain U.S. federal income tax matters\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022081469/ea170537ex8-2_jinmedical.htm) |
| 8.3 | [Opinion of Maples and Calder (Hong Kong) LLP regarding certain Cayman Islands tax matters (included in Exhibit 5.1)\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390023014263/ea173808ex5-1_jinmedical.htm) |
| 10.1 | [Employment Agreement by and between Erqi Wang (CEO) and the Registrant\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022055638/ea165658ex10-1_jinmedical.htm) |
| 10.2 | [Form of Indemnification Agreement between the Registrant and its directors and officers\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022052697/ea165190ex10-2_jinmedical.htm) |
| 10.3 | [Exclusive Cooperation and Service Agreement\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex10-3_jinmedical.htm) |
| 10.4 | [Equity Interest Pledge Agreements\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex10-4_jinmedical.htm) |
| 10.5 | [Share Disposal and Exclusive Option to Purchase Agreement\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex10-5_jinmedical.htm) |
| 10.6 | [Proxy Agreement\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex10-6_jinmedical.htm) |
| 10.7 | [Spousal Consent\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex10-7_jinmedical.htm) |
| 10.8 | [English translation of the Sales Framework Contract between the Registrant and Nissin Medical Industries Co., Ltd.\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex10-8_jinmedical.htm) |
| 10.9 | [English translation of the Rental Agreement between the Registrant and Jiangsu Shuangzheng Vehicle Industry Co., Ltd. dated April 20, 2014\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex10-9_jinmedical.htm) |
| 10.10 | [Employment Agreement by and between Ziqiang Wang (CFO) and the Registrant\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022055638/ea165658ex10-10_jinmedical.htm) |
| 14.1 | [Code of Business Conduct and Ethics of the Registrant\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022052697/ea165190ex14-1_jinmedical.htm) |
| 21.1 | [Principal Subsidiaries and Consolidated Affiliated Entities\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex21-1_jinmedical.htm) |
| 23.1 | [Consent of Friedman LLP\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390023014263/ea173808ex23-1_jinmedical.htm) |
| 23.2 | [Consent of Maples and Calder (Hong Kong) LLP (included in Exhibit 5.1)\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390023014263/ea173808ex5-1_jinmedical.htm) |
| 23.3 | [Consent of Beijing Dacheng Law Office, LLP (Shanghai) (included in 99.3)\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-3_jinmedical.htm) |
| 23.4 | [Consent of Hunter Taubman Fischer & Li LLC (included in Exhibits 8.2)\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390022081469/ea170537ex8-2_jinmedical.htm) |
| 99.1 | [Industry Report by Frost & Sullivan\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-1_jinmedical.htm) |
| 99.2 | [Consent of Frost & Sullivan\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-2_jinmedical.htm) |
| 99.3 | [Opinion of Beijing Dacheng Law Office, LLP (Shanghai), People's Republic of China counsel to the Registrant, regarding certain PRC law matters and the validity of the VIE Agreements\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-3_jinmedical.htm) |
| 99.4 | [Consent of Jourdan B. Frain\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-4_jinmedical.htm) |
| 99.5 | [Consent of Oliver St. Clair Franklin\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-5_jinmedical.htm) |
| 99.6 | [Consent of Jing Chen\*](http://www.sec.gov/Archives/edgar/data/1837821/000121390021049743/ea147457ex99-6_jinmedical.htm) |
| 107 | [Registration Fee Table\*<u>\*\*</u>](ea174732ex-fee_jinmedical.htm) |

---

\* Previously filed.

\*\* To be filed by amendment.

\*\*\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Changzhou, Jiangsu, China, on March 7, 2023.

---

| | |
|:---|:---|
| **JIN MEDICAL INTERNATIONAL LTD.** | **JIN MEDICAL INTERNATIONAL LTD.** |
| By: | /s/ *Erqi Wang* |
|  | Mr. Erqi Wang |
|  | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ *Erqi Wang* | Chief Executive Officer and Chairman of the Board of Director | March 7, 2023 |
| Name: Erqi Wang |  |  |
| /s/ Ziqiang Wang | Chief Financial Officer and Director | March 7, 2023 |
| Name: Ziqiang Wang |  |  |

---

**SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES**

Pursuant to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement thereto in New York, New York on March 7, 2023.

Cogency Global Inc.

---

| | | |
|:---|:---|:---|
| By: | /s/ Colleen A. De Vries | /s/ Colleen A. De Vries |
|  | Name: | Colleen A. De Vries |
|  | Title: | Senior Vice President |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

(Form Type)

**JIN MEDICAL INTERNATIONAL LTD.**

(Exact Name of Registrant as Specified in its Charter)

(Translation of Registrant's Name into English)

<u>Table 1: Newly Registered and Carry Forward Securities</u>

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security<br> Type** | **Security Class<br> Title** | **Fee<br> Calculation<br> or Carry<br> Forward<br> Rule** | **Amount<br> Registered** | **Proposed<br> Maximum<br> Offering<br> Price Per<br> Unit** | **Proposed<br> Maximum<br> Offering<br> Price Per<br> Unit** | **Maximum<br> Aggregate<br> Offering<br> Price** | **Maximum<br> Aggregate<br> Offering<br> Price** | **Fee Rate** | **Amount of<br> Registration<br> Fee** | **Amount of<br> Registration<br> Fee** | **Carry<br> Forward<br> Form<br> Type** | **Carry<br> Forward<br> File<br> Number** | **Carry<br> Forward<br> Initial<br> effective<br> date** | **Filing Fee<br> Previously<br> Paid In<br> Connection<br> with Unsold<br> Securities to<br> be Carried<br> Forward** |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to Be Paid | Equity | Ordinary shares, par value US$0.001 per share **<sup>(1)</sup>** | Rule 457(a) | 1437500 | US$ | 9 | US$ | 12937500 | US$110.2 per million dollars | US$ | 1425.71 |  |  |  |  |
| Fees to Be Paid | Equity | <br>Representative's warrants **<sup>(2)</sup>** | Rule 457(g) |  | US$ |  | US$ |  |  | US$ |  |  |  |  |  |
| Fees to Be Paid | Equity | Ordinary shares underlying the representative's warrants **<sup>(3)(4)</sup>** | Rule 457(a),(g) | 43125 | US$ | 11.7 | US$ | 504562.5 | US$110.2 per million dollars | US$ | 55.60 |  |  |  |  |
| Fees Previously Paid | Equity | Ordinary shares, par value US$0.001 per share | 457(a) |  | US$ | 6 | US$ | 33000000 | US$109.1 per million dollars | US$ | 3600.30 |  |  |  |  |
| Fees Previously Paid | Equity | Ordinary shares, par value US$0.001 per share | 457(a) |  | US$ | 6 | US$ | 4085500 | US$92.70 per million dollars | US$ | 378.73 |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  |  | US$ | 13442062.5 |  | US$ | 1481.32 |  |  |  |  |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |  | US$ | 3980 |  |  |  |  |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |  |  |  |  |  |  |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  |  |  |  |  |  |  |  |  |

---

(1) Including
1,250,000 Ordinary Shares to be sold in this offering and up to 187,500 Ordinary Shares that may be purchased by the Underwriter pursuant
to their 15% option to purchase additional shares, to prevent dilution resulting from share splits, share dividends, or similar transactions.
Such amount is estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the Securities Act
and reflects the maximum offering price of securities registered hereunder.

(2) No
fee required pursuant to Rule 457(g) of the Securities Act.

(3) The Registrant agreed to issue, on the closing date of this
offering, warrants (the "Underwriters' Warrants"), to Prime Number Capital, LLC, the representative of the underwriters,
up to 43,125, in an amount equal to 3% of the aggregate number of Ordinary Shares (1,437,500 Ordinary Shares) sold in the offering.

(4) The
Underwriter's Warrants will have an exercise price equal to 130% of the offering price of the Ordinary Shares offered hereby. The
Underwriters' Warrants are exercisable commencing six months after the commencement of the sale of this offering and will terminate
five years after the commencement of the sale of this offering. For a description of other terms of the Representative's Warrants
and a description of the other compensation to be received by the underwriters, see "Underwriting".